Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Tools & Techniques Diagnostics & prognostics

The Truth About Personal Genetic Tests

Direct-to-consumer genetic tests like 23andMe have evolved substantially in the last decade, faster than society’s ability to comprehend their medical, scientific, and ethical implications.

The path for 23andMe has been a rocky, convoluted one as it initially struggled to balance its business interests with regulatory requirements. The company started with a much larger 250+ gene assay that, in addition to testing for genetic ancestry and lighthearted traits, such as eye color or the ability to smell asparagus, tested for BRCA genes and genes associated with alcoholism, obesity, Alzheimer’s and Parkinson’s. In November 2013, 23andMe was temporarily shut down by the FDA for failing to prove its assays were accurate and reliable despite numerous requests. It was a harsh but necessary move by the FDA. As any physician knows, the first questions about any assay are: how reliable it is? What are the positive and negative predictive values? Is the result clinically meaningful?

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Suneel Deepak Kamath

Suneel Deepak Kamath is Hematology/Oncology Fellow at Northwestern Memorial Hospital, Chicago, USA.

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register